TheraQuest's IND For Abuse Deterrent Strong Opioid (TQ-1015) Accepted By FDA TheraQuest Biosciences, Inc. a development stage pain management company announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using SECUREL(R), TheraQuest's proprietary abuse deterrent technology.
Source: www.medicalnewstoday.comPatient Pain Likely When Doctors Ask End-Of-Life Questions When treatment options dwindle or are exhausted, terminally ill-patients often opt for pain management and comfort over life-extending therapies.
Source: www.medicalnewstoday.comDIA's Pharmacovigilance And Risk Management Conference To Address Current Complexities And Controversies The Drug Information Association will host its 8th Annual DIA Conference for Contemporary Pharmacovigilance and Risk Management Strategies (January 11-15; Washington, DC).
Source: www.medicalnewstoday.comClinical Data Show Long Acting Human Growth Hormone ARX201 Is Safe And Well Tolerated Ambrx Inc. announced Phase I/II clinical trial data demonstrating that ARX201, the company's long-acting human growth hormone (hGH) analogue developed in collaboration with Merck Serono, normalized insulin-like growth factor I (IGF-I) levels while delivering an acceptable safety and tolerability profile in adults with Growth Hormone deficiency.
Source: www.medicalnewstoday.comEuropaBio And EBE Congratulate EU Leaders On The Commission Communication On Rare Diseases EuropaBio and EBE would like to congratulate the European Commission on its draft Communication and proposed Council Recommendation on Rare Diseases (1). These are timely and vital documents, not only for the rare disease community, but also for the European society at large. This is a unique opportunity to identify core areas where a concerted effort can make a real difference to the effective diagnosis, treatment and care for rare diseases in the EU.
Source: www.medicalnewstoday.comSmiths Medical Announces New Partnership With Great Ormond Street Hospital And University College London Smiths Medical announces a new five-year research partnership with Great Ormond Street Hospital (GOSH), the Institute of Child
Health (ICH) and University College London (UCL). The partnership will provide sponsorship for the Smiths Medical Professor of Anaesthesia and Critical Care at UCL.
Source: www.medicalnewstoday.comFDA Approves Low-dose Regimen Of PREMARIN Vaginal Cream To Treat Moderate To Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse PREMARIN(R) (conjugated estrogens) Vaginal Cream 0.5 g has been approved by the U.S. Food and Drug Administration (FDA) for a new indication and a new less frequent twice-weekly dosing regimen to treat moderate to severe postmenopausal dyspareunia (painful sexual intercourse) announced Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).
Source: www.medicalnewstoday.com
# posted by Network @ 5:00 PM
